company background image
IMR

Imricor Medical Systems ASX:IMR Stock Report

Last Price

AU$0.16

Market Cap

AU$21.5m

7D

39.1%

1Y

-92.2%

Updated

28 Jun, 2022

Data

Company Financials +
IMR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

IMR Stock Overview

Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States.

Imricor Medical Systems Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Imricor Medical Systems
Historical stock prices
Current Share PriceAU$0.16
52 Week HighAU$2.10
52 Week LowAU$0.10
Beta0.49
1 Month Change-43.86%
3 Month Change-77.14%
1 Year Change-92.16%
3 Year Changen/a
5 Year Changen/a
Change since IPO-88.97%

Recent News & Updates

Mar 23
Will Imricor Medical Systems (ASX:IMR) Spend Its Cash Wisely?

Will Imricor Medical Systems (ASX:IMR) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

IMRAU Medical EquipmentAU Market
7D39.1%6.7%2.8%
1Y-92.2%-30.8%-9.6%

Return vs Industry: IMR underperformed the Australian Medical Equipment industry which returned -30.8% over the past year.

Return vs Market: IMR underperformed the Australian Market which returned -9.6% over the past year.

Price Volatility

Is IMR's price volatile compared to industry and market?
IMR volatility
IMR Average Weekly Movement17.6%
Medical Equipment Industry Average Movement9.7%
Market Average Movement9.8%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market4.3%

Stable Share Price: IMR is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: IMR's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2006n/aSteve Wedanhttps://www.imricor.com

Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States. The company’s principal products include the Advantage-MR EP Recorder/Stimulator system, an EP recording system and integrated cardiac stimulator; Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter; and Vision-MR Dispersive Electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices.

Imricor Medical Systems Fundamentals Summary

How do Imricor Medical Systems's earnings and revenue compare to its market cap?
IMR fundamental statistics
Market CapUS$14.96m
Earnings (TTM)-US$19.73m
Revenue (TTM)US$696.27k

23.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMR income statement (TTM)
RevenueUS$696.27k
Cost of RevenueUS$2.59m
Gross Profit-US$1.90m
Other ExpensesUS$17.84m
Earnings-US$19.73m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.14
Gross Margin-272.30%
Net Profit Margin-2,834.05%
Debt/Equity Ratio0%

How did IMR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is IMR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMR?

Other financial metrics that can be useful for relative valuation.

IMR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does IMR's PS Ratio compare to its peers?

IMR PS Ratio vs Peers
The above table shows the PS ratio for IMR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.3x
AMT Allegra Orthopaedics
3.5xn/aAU$18.8m
RHT Resonance Health
7.4xn/aAU$26.7m
AHC Austco Healthcare
0.9xn/aAU$28.7m
CMP Compumedics
0.8xn/aAU$28.3m
IMR Imricor Medical Systems
23x85.2%AU$23.0m

Price-To-Sales vs Peers: IMR is expensive based on its Price-To-Sales Ratio (23x) compared to the peer average (3.1x).


Price to Earnings Ratio vs Industry

How does IMR's PE Ratio compare vs other companies in the AU Medical Equipment Industry?

Price-To-Sales vs Industry: IMR is expensive based on its Price-To-Sales Ratio (23x) compared to the Australian Medical Equipment industry average (5x)


Price to Sales Ratio vs Fair Ratio

What is IMR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio23x
Fair PS Ratio0.01x

Price-To-Sales vs Fair Ratio: IMR is expensive based on its Price-To-Sales Ratio (23x) compared to the estimated Fair Price-To-Sales Ratio (0x).


Share Price vs Fair Value

What is the Fair Price of IMR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IMR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IMR's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMR's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Imricor Medical Systems forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


45.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMR's revenue (85.2% per year) is forecast to grow faster than the Australian market (5.2% per year).

High Growth Revenue: IMR's revenue (85.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IMR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Imricor Medical Systems performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-27.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IMR is currently unprofitable.

Growing Profit Margin: IMR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMR is unprofitable, and losses have increased over the past 5 years at a rate of 27.9% per year.

Accelerating Growth: Unable to compare IMR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (32.6%).


Return on Equity

High ROE: IMR has a negative Return on Equity (-88.09%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Imricor Medical Systems's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IMR's short term assets ($22.7M) exceed its short term liabilities ($2.7M).

Long Term Liabilities: IMR's short term assets ($22.7M) exceed its long term liabilities ($1.7M).


Debt to Equity History and Analysis

Debt Level: IMR has more cash than its total debt.

Reducing Debt: IMR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 34.5% each year


Discover healthy companies

Dividend

What is Imricor Medical Systems's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMR's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IMR has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

9.9yrs

Average management tenure


CEO

Steve Wedan (52 yo)

16.08yrs

Tenure

US$576,738

Compensation

Mr. Steve Wedan has been the Chief Executive Officer, President and Director of Imricor Medical Systems Inc. since May 23, 2006 and serves as its Executive Chairman. Mr. Wedan has medical device experience...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD576.74K) is above average for companies of similar size in the Australian market ($USD289.00K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IMR's management team is seasoned and experienced (9.9 years average tenure).


Board Members

Experienced Board: IMR's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IMR insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.3%.


Top Shareholders

Company Information

Imricor Medical Systems, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Imricor Medical Systems, Inc.
  • Ticker: IMR
  • Exchange: ASX
  • Founded: 2006
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: AU$21.539m
  • Shares outstanding: 143.59m
  • Website: https://www.imricor.com

Location

  • Imricor Medical Systems, Inc.
  • 400 Gateway Boulevard
  • Burnsville
  • Minnesota
  • 55337
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/28 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.